Publications by authors named "Rod Humerickhouse"

Claim this Profile
A
A Phase 1 and Biodistribution Study of ABT-806i, an In-Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806.
Hui K Gan, Matthew Burge, Benjamin Solomon, Sze Ting Lee, Kyle D Holen, Rod Humerickhouse

J Nucl Med· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of navitoclax, a BCL-2 and BCL-X inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study.
Sven de Vos, John P Leonard, Jonathan W Friedberg, Jasmine Zain, Kieron Dunleavy, Rod Humerickhouse

Leuk Lymphoma· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated Mechanistic Model of Minimal Residual Disease Kinetics With Venetoclax Therapy in Chronic Lymphocytic Leukemia.
Sathej Gopalakrishnan, William Wierda, Brenda Chyla, Rajeev Menon, Dale Miles, Rod Humerickhouse

Clin Pharmacol Ther· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy.
Anthony R Mato, William G Wierda, Matthew S Davids, Bruce D Cheson, Steven E Coutre, Rod A Humerickhouse

Haematologica· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.
Kirsten Fischer, Othman Al-Sawaf, Jasmin Bahlo, Anna-Maria Fink, Maneesh Tandon, Rod Humerickhouse

N Engl J Med· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.
Andrew H Wei, Stephen A Strickland, Jing-Zhou Hou, Walter Fiedler, Tara L Lin, Rod Humerickhouse

J Clin Oncol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma.
Matthew S Davids, Gottfried von Keudell, Craig A Portell, Jonathon B Cohen, David C Fisher, Rod A Humerickhouse

J Clin Oncol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy.
Steven Coutre, Michael Choi, Richard R Furman, Herbert Eradat, Leonard Heffner, Rod A Humerickhouse

Blood· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
John F Seymour, Thomas J Kipps, Barbara Eichhorst, Peter Hillmen, James D'Rozario, Rod Humerickhouse

N Engl J Med· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
Courtney D DiNardo, Keith W Pratz, Anthony Letai, Brian A Jonas, Andrew H Wei, Rod Humerickhouse

Lancet Oncol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.
Jeffrey A Jones, Anthony R Mato, William G Wierda, Matthew S Davids, Michael Choi, Rod A Humerickhouse

Lancet Oncol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy.
Kevin J Freise, Aksana K Jones, Rajeev M Menon, Maria E Verdugo, Rod A Humerickhouse

Hematol Oncol· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia.
Kevin J Freise, Aksana K Jones, Doerthe Eckert, Sven Mensing, Shekman L Wong, Rod A Humerickhouse

Clin Pharmacokinet· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax and obinutuzumab in chronic lymphocytic leukemia.
Kirsten Fischer, Othman Al-Sawaf, Anna-Maria Fink, Mark Dixon, Jasmin Bahlo, Rod Humerickhouse

Blood· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma.
Ahmed Hamed Salem, Suresh K Agarwal, Martin Dunbar, Sari L Heitner Enschede, Rod A Humerickhouse

J Clin Pharmacol· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.
Matthew S Davids, Andrew W Roberts, John F Seymour, John M Pagel, Brad S Kahl, Rod A Humerickhouse

J Clin Oncol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
John F Seymour, Shuo Ma, Danielle M Brander, Michael Y Choi, Jacqueline Barrientos, Rod A Humerickhouse

Lancet Oncol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of Venetoclax-Posaconazole Interaction in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments.
Suresh K Agarwal, Courtney D DiNardo, Jalaja Potluri, Martin Dunbar, Hagop M Kantarjian, Rod A Humerickhouse

Clin Ther· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.
Marina Konopleva, Daniel A Pollyea, Jalaja Potluri, Brenda Chyla, Leah Hogdal, Rod Humerickhouse

Cancer Discov· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis.
Aksana K Jones, Kevin J Freise, Suresh K Agarwal, Rod A Humerickhouse, Shekman L Wong

AAPS J· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
Stephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, Steven Coutre, John F Seymour, Rod Humerickhouse

Lancet Oncol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
Andrew W Roberts, Matthew S Davids, John M Pagel, Brad S Kahl, Soham D Puvvada, Rod A Humerickhouse

N Engl J Med· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study of ABT-806 in subjects with advanced solid tumors.
James M Cleary, David A Reardon, Nilofer Azad, Leena Gandhi, Geoffrey I Shapiro, Rod Humerickhouse

Invest New Drugs· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia.
Aksana Kaefer, Jianning Yang, Peter Noertersheuser, Sven Mensing, Rod Humerickhouse

Cancer Chemother Pharmacol· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Studying navitoclax, a targeted anticancer drug, in healthy volunteers--ethical considerations and risk/benefit assessments and management.
Hao Xiong, Rajendra S Pradhan, Adel Nada, Andrew P Krivoshik, Kyle D Holen, Rod Humerickhouse

Anticancer Res· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis